Latest Pneumococcal vaccine Stories
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of Respiratory and Critical Care Medicine, a publication of the American Thoracic Society.
WASHINGTON, July 22 /PRNewswire/ -- Young adults may have grown up in an era of information overload, but they have alarmingly little awareness of the risks of vaccine-preventable diseases and the need to keep up with vaccinations into adulthood, new data show.For example, 84 percent of Americans over the age of 50 know that tetanus causes lockjaw and that they need to get a tetanus shot every 10 years.
COLLEGEVILLE, Pa., July 14 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has become the first government agency to approve Prevenar 13* Valent, (Pneumococcal Conjugate Vaccine 13 Valent (Diphtheria CRM(197) Protein)) for infants and young children.
Infants who received two or three primary doses of the 7-valent pneumococcal conjugate vaccine (PCV-7) both had a decreased rate of carrying pneumococcal microorganisms that can cause pneumonia and other infections, compared to infants who were not vaccinated, according to a study in the July 8 issue of JAMA.
The Bill & Melinda Gates Foundation and the governments of Britain, Italy, Canada, Russia and Norway announced a $1.5 billion initiative on Friday to provide poor nations better access to vaccines against pneumococcal disease such as meningitis and pneumonia.
A $1.5 billion plan to save the world's poorest children from pneumococcal diseases was activated Friday in Lecce, Italy, international aid groups said. Representatives of five countries and four international aid groups officially made good on commitments promised in 2007 to speed delivery of pneumococcal vaccines that kill 1.6 million people year, including an estimated 1 million children under age 5. Italy donated $635 million, Britain $485 million, Canada $200 million, Russia $80 million,...
COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide.
WASHINGTON, June 4 /PRNewswire-USNewswire/ -- The U.S. Agency for International Development (USAID) yesterday contributed $75 million to improve and expand children's immunization programs in developing countries. The contribution is part of the overall U.S.
-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- COLLEGEVILLE, Pa., May 7 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S.
- Initiation of a first-in-man Phase I clinical trial in healthy subjects - Study aims to obtain safety and immunogenicity data of this new vaccine candidate - Initial results expected in Q4 2009 - Development of Intercell's Streptococcus pneumoniae vaccine supported by PATH VIENNA, April 7 /PRNewswire/ -- Intercell AG (VSE: ICLL) announced today that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has...
- Emitting flashes of light; glittering.